Clinical Trial Update: A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABI-007 to dacarbazine in previously untreated metastatic malignant melanoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ABI-007 (nab-paclitaxel)
• Dacarbazine (dacarbazine)

Snippet

Sponsor: Celgene | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2014-06-05